<DOC>
	<DOCNO>NCT01551069</DOCNO>
	<brief_summary>Primary Objective : - To investigate efficacy skin manifestation 16 week treatment daily regimen hydroxychloroquine sulphate ( HCQ ) patient cutaneous lupus erythematosus ( CLE ) systemic lupus erythematosus ( SLE ) active skin manifestation ( CLASI [ Cutaneous Lupus Erythematosus Disease Area Severity Index ] activity score ≥4 ) concomitant treatment without corticosteroid . Secondary Objectives : - To evaluate efficacy skin manifestation safety 16 week treatment daily regiment HCQ versus placebo reference group patient CLE SLE active skin manifestation ( CLASI activity score ≥4 ) concomitant treatment without corticosteroid . - To investigate safety 16 week treatment daily regiment HCQ patient CLE SLE active skin manifestation concomitant treatment without corticosteroid . - To investigate safety efficacy 52 week long-term treatment daily regimen HCQ patient CLE SLE - To investigate influence dose reduction corticosteroid CLE SLE patient treat HCQ concomitant corticosteroid - To investigate efficacy daily regimen HCQ systemic symptom , musculoskeletal symptom immunological parameter SLE patient .</brief_summary>
	<brief_title>Multicenter Study Assessing Efficacy &amp; Safety Hydroxychloroquine Sulfate Patients With Systemic Lupus Erythematosus Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion</brief_title>
	<detailed_description>Total 59 week ( screen ; 4 week , treatment ; 52 week , Follow-up ; 3 week )</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Lupus Erythematosus , Cutaneous</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Inclusion criterion : Patients diagnose cutaneous lupus erythematosus ( CLE ) Exclusion criterion : Patients receive corticosteroid 15mg/day equivalent dose prednisolone . Patients whose CLASI activity score less 4 point initiation Screening ( Visit 1 ) Day1 ( Visit 2 ) ( evaluated dermatology specialist ) . Patients whose fluctuation CLASI activity score ≥20 % Visit 1 Visit 2 ( evaluate dermatology specialist ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>